Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. develops, manufactures and markets professional dental products, dental technologies, oral health products and other consumable medical devices under a broad brand portfolio. News for XRAY commonly covers quarterly results, outlook updates, restructuring actions, capital allocation, debt reduction, share repurchases and changes to distribution relationships for dental equipment and connected technology solutions.
Company updates also focus on digital dentistry and imaging products, including CEREC systems, intraoral scanning, CBCT imaging, DS Core, Smart View - Detect and dental-dedicated MRI work with Siemens Healthineers. Additional product news includes Surity urinary incontinence devices from Wellspect HealthCare, along with regulatory clearances, CE markings, commercial launches, board changes and investor conference participation.
Dentsply Sirona (XRAY) will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.
Investors and other interested parties can access a live audio webcast and replay through the Investors section of the Dentsply Sirona website.
Dentsply Sirona (NASDAQ: XRAY), through Wellspect HealthCare, announced the U.S. launch of the at-home Surity™ Urinary Management System, a discreet urine collection device for people living with urinary incontinence. The system completes the Surity portfolio, which already includes Surity Female and Male External Catheters.
The device uses gentle suction with an on-demand Boost function to draw urine away from the body, offers quiet one-touch operation designed for overnight use, and incorporates carbon filters to help reduce odors. According to the company, the system aims to integrate into daily and nighttime routines to support comfort, rest and caregiver ease. It is available for home purchase at www.surity.care and is expected to be offered to healthcare institutions.
Dentsply Sirona (Nasdaq: XRAY) reported Q2 2026 net sales of $898 million, down 4.1% year over year, with GAAP gross margin of 54.9% and net income attributable to the company of $37 million, or $0.18 diluted EPS, compared to a loss in Q2 2025.
Non-GAAP results included Adjusted EBITDA of $190 million with a 21.3% margin and Adjusted EPS of $0.52, flat versus the prior year, while constant currency sales declined 6.3%. Operating cash flow rose to $99 million and free cash flow to $55 million. The company repurchased 1.3 million shares for about $12 million and expanded its partnership with Medline Sinclair to broaden Connected Technology Solutions access across Canada. Dentsply Sirona reiterated its 2026 outlook for net sales of $3.5–$3.6 billion and Adjusted EPS of $1.40–$1.50.
Dentsply Sirona (NASDAQ: XRAY) announced an expansion of its long-standing relationship with Medline Sinclair, one of Canada’s leading full-service dental distributors. Effective September 1, 2026, Medline Sinclair will begin offering Dentsply Sirona’s technology portfolio across Canada, adding to a relationship that previously focused on consumables.
The move is described as Dentsply Sirona’s sixth dealer network enhancement in 2026, supporting its strategy to broaden access to digital dentistry solutions through trusted distribution partners. The expanded agreement leverages Medline Sinclair’s nationwide sales, service, and technical network to increase access to Dentsply Sirona’s technology for Canadian dental practices.
Dentsply Sirona (Nasdaq: XRAY) will host an investor conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to review its second quarter 2026 financial results.
Earnings materials, webcast links, registration details, and the replay will be available in the Investors section of the company’s website.
Dentsply Sirona (NASDAQ:XRAY) and PDS Health announced that PDS practices have completed over five million CEREC chairside restorations, using more than 1,200 CEREC systems across the network.
The milestone highlights large-scale adoption of digital restorative workflows that support same-day treatment, predictable outcomes, and a more efficient, convenient patient experience.
Dentsply Sirona (Nasdaq: XRAY) appointed John Fortson as Executive Vice President and Chief Financial Officer, effective July 20. He brings over 25 years of experience in finance, operations, and strategy, including 13 years as CFO or CEO of global manufacturing and industrial businesses.
Fortson previously held senior roles at Kymera International and Ingevity Corporation and has led large-scale transformations, capital allocation, acquisitions, and ERP implementations. Leadership expects him to support Dentsply Sirona’s Return-to-Growth Action Plan, with a focus on disciplined execution and long-term value creation for shareholders.
Dentsply Sirona (Nasdaq: XRAY) announced an expanded U.S. partnership with Nashville Dental (NDI), a regional dental distributor in the Southeast and Mid-Atlantic.
Effective August 1, 2026, NDI will offer Dentsply Sirona’s full connected digital portfolio, including CEREC, Primescan, and digital imaging, across a nine-state territory to enhance access and support adoption.
Dentsply Sirona (Nasdaq: XRAY) will participate in the 2026 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 27, 2026, at 3:35 p.m. ET.
A live audio webcast and replay will be available via the Investors section of the company website.
Dentsply Sirona (Nasdaq: XRAY) reported Q1 2026 net sales of $880 million and GAAP gross margin of 48.5%, with a GAAP net loss attributable of $10 million (diluted loss per share $0.05).
Non-GAAP results included adjusted EBITDA of $129 million (14.7% margin) and adjusted EPS of $0.27. The company launched Smart View-Detect (FDA-cleared, CE-marked) and reiterated 2026 guidance: net sales $3.5–3.6 billion, adjusted EPS $1.40–$1.50.